The Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) trial demonstrated that rivaroxaban monotherapy was noninferior to double antithrombotic therapy (rivaroxaban and a single antiplatelet drug, i.e., aspirin or a P2Y12 inhibitor) with regard to efficacy and superior with regard to safety in patients with coronary artery disease and atrial fibrillation, even 1 year or more after PCI using drug-eluting stents [24]. The gene discussed is P2RY12; the disease is coronary artery disorder.